Feingold; Jay Marshall

Patent Applications and Registrations

Patent applications and USPTO patent grants for Feingold; Jay Marshall.The latest application filed is for "dosage regimes for the administration of an anti-cd19 adc".

Company Profile

4.6.17

Feingold; Jay Marshall - Murray Hill NJ
Feingold; Jay Marshall - Wynnewood PA
Feingold; Jay Marshall - Livingston NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Dosage Regimes For The Administration Of An Anti-cd19 Adc App 20220280651 - Feingold; Jay Marshall ; et al.	2022-09-08
Dosage regimes for the administration of an anti-CD25 ADC Grant 11,426,467 - Feingold , et al. August 30, 2	2022-08-30
Phosphatidylinositol-3-kinase Pathway Biomarkers App 20220170107 - Berkenblit; Anna ; et al.	2022-06-02
Dosage regimes for the administration of an anti-CD19 ADC Grant 11,318,211 - Feingold , et al. May 3, 2	2022-05-03
Molecular Adjuvant App 20220111065 - VAN BERKEL; Patrick Hendrikus Cornelis ; et al.	2022-04-14
Combination Therapy With An Anti-cd25 Antibody-drug Conjugate App 20220016259 - Van Berkel; Patricius Hendrikus Cornelis ; et al.	2022-01-20
Pyrrolobenzodiazepine-antibody Conjugates App 20200405873 - FEINGOLD; Jay Marshall ; et al.	2020-12-31
Dosage Regimes For The Administration Of An Anti-cd25 Adc App 20200405872 - Feingold; Jay Marshall ; et al.	2020-12-31
Combination Therapy App 20200405879 - Feingold; Jay Marshall ; et al.	2020-12-31
Dosage Regimes For The Administration Of An Anti-cd19 Adc App 20200171164 - Feingold; Jay Marshall ; et al.	2020-06-04
Phosphatidylinositol-3-kinase Pathway Biomarkers App 20190271047 - Berkenblit; Anna ; et al.	2019-09-05
Pyrrolobenzodiazepine-antibody Conjugates App 20190015524 - FEINGOLD; JAY MARSHALL ; et al.	2019-01-17
Phosphatidylinositol-3-kinase Pathway Biomarkers App 20160222467 - Berkenblit; Anna ; et al.	2016-08-04
Anti-tumor activity of CCI-779 in papillary renal cell cancer Grant 8,791,097 - Dukart , et al. July 29, 2	2014-07-29
Phosphatidylinositol-3-kinase Pathway Biomarkers App 20130189274 - Berkenblit; Anna ; et al.	2013-07-25
Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor Grant 8,338,456 - Coughlin , et al. December 25, 2	2012-12-25
CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR App 20120010240 - Coughlin; Christina Marie ; et al.	2012-01-12
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome Grant 7,727,968 - Feingold , et al. June 1, 2	2010-06-01
Anti-tumor Activity Of Cci-779 In Papillary Renal Cell Cancer App 20080255177 - DUKART; GARY ; et al.	2008-10-16
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome App 20070269430 - Feingold; Jay Marshall ; et al.	2007-11-22
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome App 20040152632 - Feingold, Jay Marshall	2004-08-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.